Number | Percentage | Median | IQR | |
---|---|---|---|---|
Gender | ||||
Male | 53 | |||
Female | 14 | |||
Age (years) | 74 | 68.5–77.0 | ||
Time from diagnosis (years) | 3 | 2.0–4.5 | ||
Smoking history | ||||
Non smoker | 19 | |||
Smoker or former smoker | 41 | |||
Forced vital capacity (% predicted) | 75.0 | 56.75–93.0 | ||
DLCO (% predicted) | 41.0 | 34.0–60.0 | ||
GAP stage (%) | ||||
I | 32.70 | |||
II | 53.10 | |||
III | 14.30 | |||
Treatment | ||||
Pirfenidone | 18 | |||
Nintedanib | 13 | |||
Untreated | 26 |